• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.

作者信息

Fujita Tetsuo, Amano Hiroyuki, Nakamura Makoto, Hirano Satoshi, Nakamura Sukeyuki

机构信息

Department of Respirology, Funabashi Municipal Medical Center, Kanasugi, Japan.

Department of Respirology, Funabashi Municipal Medical Center, Kanasugi, Japan.

出版信息

J Thorac Oncol. 2023 Sep;18(9):e93-e94. doi: 10.1016/j.jtho.2023.05.025.

DOI:10.1016/j.jtho.2023.05.025
PMID:37599053
Abstract
摘要

相似文献

1
Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.一例PD-L1表达为0%的EGFR突变型肺腺癌患者对免疫检查点抑制剂单药治疗的显著反应
J Thorac Oncol. 2023 Sep;18(9):e93-e94. doi: 10.1016/j.jtho.2023.05.025.
2
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.程序性死亡配体1表达可预测表皮生长因子受体突变阳性肺腺癌患者队列中酪氨酸激酶抑制剂的反应及更好的预后。
Clin Lung Cancer. 2015 Sep;16(5):e25-35. doi: 10.1016/j.cllc.2015.02.002. Epub 2015 Feb 19.
3
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.PD-L1 mRNA 表达在 EGFR 突变型肺腺癌中的研究。
Oncol Rep. 2018 Jul;40(1):331-338. doi: 10.3892/or.2018.6442. Epub 2018 May 16.
4
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.RAS-丝裂原活化蛋白激酶信号通路是人类肺癌中增强型程序性死亡配体1（PD-L1）表达所必需的。
PLoS One. 2016 Nov 15;11(11):e0166626. doi: 10.1371/journal.pone.0166626. eCollection 2016.
5
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].非小细胞肺癌中PD-1与PD-L1表达及表皮生长因子受体突变的相关性研究
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):623-631. doi: 10.3779/j.issn.1009-3419.2021.102.31. Epub 2021 Aug 30.
6
Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.肺腺癌的异质性成分赋予其独特的 EGFR 突变和 PD-L1 表达。
BMC Cancer. 2020 Feb 24;20(1):148. doi: 10.1186/s12885-020-6631-z.
7
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.尽管存在表皮生长因子受体（EGFR）种系突变，但转移性非小细胞肺癌（NSCLC）对免疫检查点抑制剂仍有长期反应。病例报告。
Lung Cancer. 2022 Dec;174:186-187. doi: 10.1016/j.lungcan.2022.09.005. Epub 2022 Sep 10.
8
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.EGFR 和 HER2 突变型转移性 NSCLC 的亚型影响免疫检查点抑制剂的反应。
Clin Lung Cancer. 2021 Jul;22(4):253-259. doi: 10.1016/j.cllc.2020.12.015. Epub 2021 Jan 7.
9
Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.贝伐珠单抗联合化疗治疗 ALK/EGFR 共突变和 PD-L1 过表达肺腺癌的成功管理。
Angiogenesis. 2022 Feb;25(1):5-8. doi: 10.1007/s10456-021-09811-8. Epub 2021 Aug 3.
10
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制，并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.

引用本文的文献

1
Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach.转变肺癌管理模式：多学科方法成功应用免疫检查点抑制剂的一个有前景的案例研究
Diagnostics (Basel). 2024 Sep 28;14(19):2159. doi: 10.3390/diagnostics14192159.
2
Molecular subtypes and nomogram for predicting the prognosis of cervical cancer based on a matrix-immune signature.基于基质免疫特征预测宫颈癌预后的分子亚型与列线图
Discov Oncol. 2024 Sep 4;15(1):405. doi: 10.1007/s12672-024-01265-w.